Management Team Ronald A. Martell - Chief Executive Officer Michael S. Perry, DVM, Ph.D., FRCVS - President and Chief Medical Officer Greg Weaver - Chief Financial Officer and Senior Vice President, Finance Cheni Kwok, Ph.D., CLP - Senior Vice President, Corporate Development Anna Lewak Wight, J.D., CLP - Vice President, Legal and Corporate Secretary Ronald A. Martell Chief Executive Officer Ronald A. Martell was appointed Chief Executive Officer in February 2010. He served as President and Chief Operating Officer of the company from May 2007 to February 2010. Mr. Martell joined the company's board of directors in June 2006. Mr. Martell served as Senior Vice President, Commercial Operations of ImClone Systems Incorporated from January 2004 to August 2006. While at ImClone, Mr. Martell was responsible for overseeing the company's sales, marketing, and project and alliance management. Mr. Martell joined ImClone in November 1998 as Vice President, Marketing. From 1988 to 1998, he served in a variety of positions at Genentech, Inc., most recently as Group Manager, Oncology Products. Michael S. Perry, DVM, Ph.D., FRCVS President and Chief Medical Officer Michael S. Perry was appointed President and Chief Medical Officer in February 2010. Dr. Perry has been a consultant to the company since September 2009 and is a Venture Partner with Bay City Capital LLC (since November 2005). He was Chief Development Officer at VIA Pharmaceuticals, Inc., a publicly held drug development company, from April 2005 until May 2009. Prior thereto, he served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from June 2003 to April 2005. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter BioScience. From 1997 to 2000, Dr. Perry was President and Chief Executive Officer of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp., and from 1994 to 1997, he was Vice President of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals). Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Pharmacology and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is also a graduate of the International Management Program at Harvard Business School. Greg Weaver Chief Financial Officer and Senior Vice President, Finance Gregory L. Weaver was appointed Chief Financial Officer and Senior Vice President, Finance in February 2009. Prior to joining the company, Mr. Weaver served as Chief Financial Officer of Talyst Inc., a privately held pharmacy automation information technology company, from April 2007 to December 2008. Prior to that, he served as Senior Vice President and Chief Financial Officer of Sirna Therapeutics, a public RNAI therapeutics company, from February 2006 until sale of the company to Merck, Inc. in December 2006. From April 2002 to September 2005, Mr. Weaver was Chief Financial Officer of Nastech Pharmaceuticals, a public drug delivery company. From April 1999 to April 2002, Mr. Weaver was Chief Financial Officer of Ilex Oncology, Inc., a public cancer drug development company, and from 1996 to 1998, he was Chief Financial Officer of Prism Technologies, a privately held medical device manufacturer. In addition, Mr. Weaver held increasingly senior positions with Fidelity Capital in Boston and Arthur Andersen LLP. Mr. Weaver has served as a director and the chairman of the audit committee of Celsion Corp., a public oncology drug development company, since 2005, and as a director and the chairman of the audit committee of SCOLR Pharmaceuticals, a public drug delivery company, from 2007 to 2009. Mr. Weaver is a certified public accountant and received his M.B.A. in finance from Boston College and his B.S. in accounting from Trinity University. Cheni Kwok, Ph.D., CLP Senior Vice President, Corporate Development Cheni Kwok joined Poniard as the Vice President of Business Development in July 2006. Previously, Dr. Kwok was Director of Business Development at Celera Genomics from 2004 to 2006, where she led the business development efforts for Celera's small molecule therapeutics programs. Prior to Celera, Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc. from 2000 to 2004, where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham Pharmaceuticals from 1997 to 2000. She received a bachelor's degree in biotechnology from Imperial College of Science, Technology and Medicine, University of London, U.K. and a Ph.D. in human molecular genetics from the University of Cambridge, U.K. Dr. Kwok obtained the Certified Licensing Professional (CLP™) credential established by the Licensing Executives Society (USA and Canada). Anna Lewak Wight, J.D., CLP Vice President, Legal and Corporate Secretary Anna Lewak Wight joined the company in 1994. Previously, she was an equity partner in the law firm of Morrison & Foerster, managing its Seattle intellectual property practice from 1993 to 1994. Prior to Morrison & Foerster, Ms. Wight was also an equity partner in the intellectual property law firm of Harness, Dickey and Pierce, where she practiced from 1986 to 1993, and established and chaired the Biotechnology and Medical Arts Group. Ms. Wight has worked on many high-profile biotechnical and biomedical projects for academic and research institutions, including gene therapy for cystic fibrosis and neurofibromatosis and CD28 immunoregulation. She received a J.D. from Wayne State University Law School and an M.S. from the Genetics Program at Michigan State University. She also obtained the Certified Licensing Professional (CLP™) credential established by the Licensing Executives Society (USA and Canada).